SEC Form 4 · accession 0000899866-15-000146
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Hallal
Officer — CEO · Director
Period of report
Aug 4, 2015
Accepted (ET)
Aug 5, 2015 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Aug 4, 2015 | S | 612 | $196.52 | D | 143,516 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.